Trisomy 21 consistently activates the interferon response

eLife

Volumn 5, Issue JULY, 2016, Pages

  Sullivan, Kelly D ^a,b,c   Lewis, Hannah C ^a   Hill, Amanda A ^a   Pandey, Ahwan ^a,b,c   Jackson, Leisa P ^a,b,c   Cabral, Joseph M ^a,b,c   Smith, Keith P ^a   Liggett, L Alexander ^a   Gomez, Eliana B ^a,b,c   Galbraith, Matthew D ^a,b,c   Degregori, James ^a,d   Espinosa, Joaquín M ^a,b,c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^d Children's Hospital Colorado   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; RUXOLITINIB; SHORT HAIRPIN RNA; STAT1 PROTEIN; TRISOMY 21; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL VIABILITY; DOWN REGULATION; DOWN SYNDROME; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RCAN1 GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; UPREGULATION; WESTERN BLOTTING; CELL CULTURE; FIBROBLAST; GENE EXPRESSION PROFILING; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; MONOCYTE; PATHOLOGY; PHYSIOLOGY; T LYMPHOCYTE;

CELLS, CULTURED; DOWN SYNDROME; FIBROBLASTS; GENE EXPRESSION PROFILING; HUMANS; IMMUNITY, INNATE; INTERFERONS; MONOCYTES; T-LYMPHOCYTES;

EID: 84986186156     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.16220     Document Type: Article

References (88)

1. Ahmed MM, Dhanasekaran AR, Tong S, Wiseman FK, Fisher EM, Tybulewicz VL, Gardiner KJ. 2013. Protein profiles in Tc1 mice implicate novel pathway perturbations in the Down syndrome brain. Human Molecular Genetics 22:1709–1724. doi: 10.1093/hmg/ddt017
2. Alexander M, Petri H, Ding Y, Wandel C, Khwaja O, Foskett N. 2016. Morbidity and medication in a large population of individuals with Down syndrome compared to the general population. Developmental Medicine and Child Neurology 58:246–254. doi: 10.1111/dmcn.12868
3. Anders S, Pyl PT, Huber W. 2015. HTSeq–a Python framework to work with high-throughput sequencing data. Bioinformatics 31:166–169. doi: 10.1093/bioinformatics/btu638
4. Andrews S. 2010. FastQC: A quality control tool for high throughput sequence data. Http://www.bioinformatics. babraham.ac.uk/projects/fastqc/.
5. Anwar AJ, Walker JD, Frier BM. 1998. Type 1 diabetes mellitus and Down’s syndrome: prevalence, management and diabetic complications. Diabetic Medicine 15:160–163. doi: 10.1002/(SICI)1096-9136(199802)15:2<160:AID-DIA537>3.0.CO;2-J
6. Arabi A, Wu S, Ridderstråle K, Bierhoff H, Shiue C, Fatyol K, Fahlén S, Hydbring P, Söderberg O, Grummt I, Larsson LG, Wright AP. 2005. c-Myc associates with ribosomal DNA and activates RNA polymerase I transcription. Nature Cell Biology 7:303–310. doi: 10.1038/ncb1225
7. Barlow CF, Priebe CJ, Mulliken JB, Barnes PD, Mac Donald D, Folkman J, Ezekowitz RA. 1998. Spastic diplegia as a complication of interferon Alfa-2a treatment of hemangiomas of infancy. Journal of Pediatrics 132:527–530. doi: 10.1016/S0022-3476(98)70034-4
8. Boon K, Caron HN, van Asperen R, Valentijn L, Hermus MC, van Sluis P, Roobeek I, Weis I, Voûte PA, Schwab M, Versteeg R, L Valentijn R, Asperen van, I, Roobeek P. Sluis van 2001. N-myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis. The EMBO Journal 20:1383–1393. doi: 10.1093/emboj/20.6.1383
9. Bratman SV, Horst KC, Carlson RW, Kapp DS. 2014. Solid malignancies in individuals with Down syndrome: a case presentation and literature review. Journal of the National Comprehensive Cancer Network 12:1537–1545.
10. Cerami EG, Gross BE, Demir E, Rodchenkov I, Babur O, Anwar N, Schultz N, Bader GD, Sander C. 2011. Pathway commons, a web resource for biological pathway data. Nucleic Acids Research 39:D685–D690. doi: 10.1093/nar/gkq1039
11. Choi H, Kim S, Fermin D, Tsou CC, Nesvizhskii AI. 2015. QPROT: Statistical method for testing differential expression using protein-level intensity data in label-free quantitative proteomics. Journal of Proteomics 129: 121–126. doi: 10.1016/j.jprot.2015.07.036
12. Costa V, Angelini C, D’Apice L, Mutarelli M, Casamassimi A, Sommese L, Gallo MA, Aprile M, Esposito R, Leone L, Donizetti A, Crispi S, Rienzo M, Sarubbi B, Calabro` R, Picardi M, Salvatore P, Infante T, De Berardinis P, Napoli C, et al. 2011. Massive-scale RNA-Seq analysis of non ribosomal transcriptome in human trisomy 21. PLoS One 6:e18493. doi: 10.1371/journal.pone.0018493
13. Crow YJ, Manel N. 2015. Aicardi-goutières syndrome and the type I interferonopathies. Nature Reviews Immunology 15:429–440. doi: 10.1038/nri3850
14. Das I, Park JM, Shin JH, Jeon SK, Lorenzi H, Linden DJ, Worley PF, Reeves RH. 2013. Hedgehog agonist therapy corrects structural and cognitive deficits in a Down syndrome mouse model. Science Translational Medicine 5: 201ra120. doi: 10.1126/scitranslmed.3005983
15. de Sola S, de la Torre R, Sánchez-Benavides G, Benejam B, Cuenca-Royo A, Del Hoyo L, Rodríguez J, Catuara-Solarz S, Sanchez-Gutierrez J, Dueñas-Espin I, Hernandez G, Peña-Casanova J, Langohr K, Videla S, Blehaut H, Farre M, Dierssen M, TESDAD Study Group. 2015. A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials. Frontiers in Psychology 6:708. doi: 10.3389/fpsyg.2015.00708
16. Do LH, Mobley WC, Singhal N. 2015. Questioned validity of gene expression dysregulated domains in Down’s syndrome. F1000Research 4:269. doi: 10.12688/f1000research.6735.1
17. Donner AJ, Ebmeier CC, Taatjes DJ, Espinosa JM. 2010. CDK8 is a positive regulator of transcriptional elongation within the serum response network. Nature Structural & Molecular Biology 17:194–201. doi: 10.1038/nsmb.1752
18. Galbraith MD, Allen MA, Bensard CL, Wang X, Schwinn MK, Qin B, Long HW, Daniels DL, Hahn WC, Dowell RD, Espinosa JM. 2013. HIF1A employs CDK8-mediator to stimulate RNAPII elongation in response to hypoxia. Cell 153:1327–1339. doi: 10.1016/j.cell.2013.04.048
19. Gold L, Walker JJ, Wilcox SK, Williams S. 2012. Advances in human proteomics at high scale with the SOMAscan proteomics platform. New Biotechnology 29:543–549. doi: 10.1016/j.nbt.2011.11.016
20. Grether JK, Nelson KB, Dambrosia JM, Phillips TM. 1999. Interferons and cerebral palsy. Journal of Pediatrics 134:324–332. doi: 10.1016/S0022-3476(99)70458-0
21. Gupta R, Kim S, Taylor MW, Wong JB, McQuillan GM, McHutchison JG, Poynard T. 2012. Suppression of ribosomal protein synthesis and protein translation factors by Peg-interferon alpha/ribavirin in HCV patients blood mononuclear cells (PBMC). Journal of Translational Medicine 10:54. doi: 10.1186/1479-5876-10-54
22. Hasle H, Friedman JM, Olsen JH, Rasmussen SA. 2016. Low risk of solid tumors in persons with Down syndrome. Genetics in Medicine. doi: 10.1038/gim.2016.23
23. Hathout Y, Brody E, Clemens PR, Cripe L, DeLisle RK, Furlong P, Gordish-Dressman H, Hache L, Henricson E, Hoffman EP, Kobayashi YM, Lorts A, Mah JK, McDonald C, Mehler B, Nelson S, Nikrad M, Singer B, Steele F, Sterling D, et al. 2015. Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy. PNAS 112:7153–7158. doi: 10.1073/pnas.1507719112
24. Hinnebusch AG. 2014. The scanning mechanism of eukaryotic translation initiation. Annual Review of Biochemistry 83:779–812. doi: 10.1146/annurev-biochem-060713-035802
25. Huang C, Liu LY, Li ZF, Wang P, Ni L, Song LP, Xu DH, Song TS. 2008. Effects of small interfering RNAs targeting MAPK1 on gene expression profile in HeLa cells as revealed by microarray analysis. Cell Biology International 32:1081–1090. doi: 10.1016/j.cellbi.2008.04.019
26. Iwamoto T, Yamada A, Yuasa K, Fukumoto E, Nakamura T, Fujiwara T, Fukumoto S. 2009. Influences of interferon-gamma on cell proliferation and interleukin-6 production in Down syndrome derived fibroblasts. Archives of Oral Biology 54:963–969. doi: 10.1016/j.archoralbio.2009.07.009
27. Iyer AM, van Scheppingen J, Milenkovic I, Anink JJ, Adle-Biassette H, Kovacs GG, Aronica E. 2014. mTOR Hyperactivation in Down syndrome hippocampus appears early during development. Journal of Neuropathology & Experimental Neurology 73:671–683. doi: 10.1097/NEN.0000000000000083
28. Jabbari A, Dai Z, Xing L, Cerise JE, Ramot Y, Berkun Y, Sanchez GA, Goldbach-Mansky R, Christiano AM, Clynes R, Zlotogorski A. 2015. Reversal of alopecia areata following treatment with the JAK1/2 inhibitor baricitinib. EBioMedicine 2:351–355. doi: 10.1016/j.ebiom.2015.02.015
29. Johnson TC, Lerner MP, Lancz GJ. 1968. Inhibition of protein synthesis in noninfected L cells by partially purified interferon preparations. Journal of Cell Biology 36:617–624. doi: 10.1083/jcb.36.3.617
30. Keystone EC, Taylor PC, Drescher E, Schlichting DE, Beattie SD, Berclaz PY, Lee CH, Fidelus-Gort RK, Luchi ME, Rooney TP, Macias WL, Genovese MC. 2015. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Annals of the Rheumatic Diseases 74:333–340. doi: 10.1136/annrheumdis-2014-206478
31. Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. 2013. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biology 14:R36. doi: 10.1186/gb-2013-14-4-r36
32. Kim S, Li Q, Dang CV, Lee LA. 2000. Induction of ribosomal genes and hepatocyte hypertrophy by adenovirus-mediated expression of c-Myc in vivo. PNAS 97:11198–11202. doi: 10.1073/pnas.200372597
33. Krämer A, Green J, Pollard J, Tugendreich S. 2014. Causal analysis approaches in ingenuity pathway analysis. Bioinformatics 30:523–530. doi: 10.1093/bioinformatics/btt703
34. Lee HC, Tan KL, Cheah PS, Ling KH. 2016. Potential role of JAK-STAT signaling pathway in the neurogenic-to-gliogenic shift in down syndrome brain. Neural Plasticity 2016:7434191. doi: 10.1155/2016/7434191
35. Letourneau A, Santoni FA, Bonilla X, Sailani MR, Gonzalez D, Kind J, Chevalier C, Thurman R, Sandstrom RS, Hibaoui Y, Garieri M, Popadin K, Falconnet E, Gagnebin M, Gehrig C, Vannier A, Guipponi M, Farinelli L, Robyr D, Migliavacca E, et al. 2014. Domains of genome-wide gene expression dysregulation in Down’s syndrome. Nature 508:345–350. doi: 10.1038/nature13200
36. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R, 1000 Genome Project Data Processing Subgroup. 2009. The sequence alignment/map format and SAMtools. Bioinformatics 25:2078–2079. doi: 10.1093/bioinformatics/btp352
37. Li Z, Yu T, Morishima M, Pao A, LaDuca J, Conroy J, Nowak N, Matsui S, Shiraishi I, Yu YE. 2007. Duplication of the entire 22.9 Mb human chromosome 21 syntenic region on mouse chromosome 16 causes cardiovascular and gastrointestinal abnormalities. Human Molecular Genetics 16:1359–1366. doi: 10.1093/hmg/ddm086
38. Lindvall C, Hou M, Komurasaki T, Zheng C, Henriksson M, Sedivy JM, Björkholm M, Teh BT, Nordenskjöld M, Xu D. 2003. Molecular characterization of human telomerase reverse transcriptase-immortalized human fibroblasts by gene expression profiling: activation of the epiregulin gene. Cancer Research 63:1743–1747.
39. Ling KH, Hewitt CA, Tan KL, Cheah PS, Vidyadaran S, Lai MI, Lee HC, Simpson K, Hyde L, Pritchard MA, Smyth GK, Thomas T, Scott HS. 2014. Functional transcriptome analysis of the postnatal brain of the Ts1Cje mouse model for Down syndrome reveals global disruption of interferon-related molecular networks. BMC Genomics 15:624. doi: 10.1186/1471-2164-15-624
40. Love MI, Huber W, Anders S. 2014. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biology 15:550. doi: 10.1186/s13059-014-0550-8
41. Malinge S, Bliss-Moreau M, Kirsammer G, Diebold L, Chlon T, Gurbuxani S, Crispino JD. 2012. Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of down syndrome. Journal of Clinical Investigation 122:948–962. doi: 10.1172/JCI60455
42. Malinge S, Chlon T, Doré LC, Ketterling RP, Tallman MS, Paietta E, Gamis AS, Taub JW, Chou ST, Weiss MJ, Crispino JD, Figueroa ME. 2013. Development of acute megakaryoblastic leukemia in down syndrome is associated with sequential epigenetic changes. Blood 122:e33–43. doi: 10.1182/blood-2013-05-503011
43. Maroun LE, Heffernan TN, Hallam DM. 2000. Partial IFN-alpha/beta and IFN-gamma receptor knockout trisomy 16 mouse fetuses show improved growth and cultured neuron viability. Journal of Interferon & Cytokine Research 20:197–203. doi: 10.1089/107999000312612
44. Maroun LE. 1978. Interferon-mediated effect on ribosomal RNA metabolism. Biochimica Et Biophysica Acta 517: 109–114. doi: 10.1016/0005-2787(78)90038-2
45. Maroun LE. 1995. Anti-interferon immunoglobulins can improve the trisomy 16 mouse phenotype. Teratology 51:329–335. doi: 10.1002/tera.1420510509
46. McGlasson S, Jury A, Jackson A, Hunt D. 2015. Type I interferon dysregulation and neurological disease. Nature Reviews Neurology 11:515–523. doi: 10.1038/nrneurol.2015.143
47. McKeage K. 2015. Ruxolitinib: A review in polycythaemia vera. Drugs 75:1773–1781. doi: 10.1007/s40265-015-0470-2
48. Mehan MR, Williams SA, Siegfried JM, Bigbee WL, Weissfeld JL, Wilson DO, Pass HI, Rom WN, Muley T, Meister M, Franklin W, Miller YE, Brody EN, Ostroff RM. 2014. Validation of a blood protein signature for non-small cell lung cancer. Clinical Proteomics 11:32. doi: 10.1186/1559-0275-11-32
49. Moisan A, Lee YK, Zhang JD, Hudak CS, Meyer CA, Prummer M, Zoffmann S, Truong HH, Ebeling M, Kiialainen A, Gérard R, Xia F, Schinzel RT, Amrein KE, Cowan CA. 2015. White-to-brown metabolic conversion of human adipocytes by JAK inhibition. Nature Cell Biology 17:57–67. doi: 10.1038/ncb3075
50. Müller M, Briscoe J, Laxton C, Guschin D, Ziemiecki A, Silvennoinen O, Harpur AG, Barbieri G, Witthuhn BA, Schindler C. 1993. The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and -gamma signal transduction. Nature 366:129–135. doi: 10.1038/366129a0
51. Padron E, Dezern A, Andrade-Campos M, Vaddi K, Scherle P, Zhang Q, Ma Y, Balasis ME, Tinsley S, Ramadan H, Zimmerman C, Steensma DP, Roboz GJ, Lancet JE, List AF, Sekeres MA, Komrokji RS., Myelodysplastic Syndrome Clinical Research Consortium. 2016. A multi-institution phase I trial of ruxolitinib in patients with chronic myelomonocytic leukemia (CMML). Clinical Cancer Research 22:3746–3754. doi: 10.1158/1078-0432.CCR-15-2781
52. Perluigi M, Di Domenico F, Butterfield DA. 2015. mTOR signaling in aging and neurodegeneration: At the crossroad between metabolism dysfunction and impairment of autophagy. Neurobiology of Disease 84:39–49. doi: 10.1016/j.nbd.2015.03.014
53. Plosker GL. 2015. Ruxolitinib: a review of its use in patients with myelofibrosis. Drugs 75:297–308. doi: 10.1007/s40265-015-0351-8
54. Quintás-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, Caulder E, Wen X, Li Y, Waeltz P, Rupar M, Burn T, Lo Y, Kelley J, Covington M, Shepard S, Rodgers JD, Haley P, Kantarjian H, Fridman JS, et al. 2010. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115:3109–3117. doi: 10.1182/blood-2009-04-214957
55. Richardson SJ, Willcox A, Bone AJ, Morgan NG, Foulis AK. 2011. Immunopathology of the human pancreas in type-I diabetes. Seminars in Immunopathology 33:9–21. doi: 10.1007/s00281-010-0205-0
56. Roberts I, Izraeli S. 2014. Haematopoietic development and leukaemia in Down syndrome. British Journal of Haematology 167:587–599. doi: 10.1111/bjh.13096
57. Scarpato M, Esposito R, Evangelista D, Aprile M, Ambrosio MR, Angelini C, Ciccodicola A, Costa V. 2014. AnaLysis of Expression on human chromosome 21, ALE-HSA21: a pilot integrated web resource. Database 2014:bau009. doi: 10.1093/database/bau009
58. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, Rice CM. 2011. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472:481–485. doi: 10.1038/nature09907
59. Shi JG, Chen X, Lee F, Emm T, Scherle PA, Lo Y, Punwani N, Williams WV, Yeleswaram S. 2014. The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK ½ inhibitor, in healthy volunteers. Journal of Clinical Pharmacology 54:1354–1361. doi: 10.1002/jcph.354
60. Shuai K, Horvath CM, Huang LH, Qureshi SA, Cowburn D, Darnell JE. 1994. Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell 76:821–828. doi: 10.1016/0092-8674(94)90357-3
61. Slate DL, Shulman L, Lawrence JB, Revel M, Ruddle FH. 1978. Presence of human chromosome 21 alone is sufficient for hybrid cell sensitivity to human interferon. Journal of Virology 25:319–325.
62. Sobey CG, Judkins CP, Sundararajan V, Phan TG, Drummond GR, Srikanth VK. 2015. Risk of major cardiovascular events in people with Down syndrome. PloS One 10:e0137093. doi: 10.1371/journal.pone.0137093
63. Spaner DE, Wang G, McCaw L, Li Y, Disperati P, Cussen MA, Shi Y. 2016. Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial. Haematologica 101:e192–195. doi: 10.3324/haematol.2015.135418
64. Stahl N, Boulton TG, Farruggella T, Ip NY, Davis S, Witthuhn BA, Quelle FW, Silvennoinen O, Barbieri G, Pellegrini S. 1994. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. Science 263:92–95. doi: 10.1126/science.8272873
65. Stankiewicz MJ, Crispino JD. 2013. AKT collaborates with ERG and Gata1s to dysregulate megakaryopoiesis and promote AMKL. Leukemia 27:1339–1347. doi: 10.1038/leu.2013.33
66. Sullivan KD, Padilla-Just N, Henry RE, Porter CC, Kim J, Tentler JJ, Eckhardt SG, Tan AC, DeGregori J, Espinosa JM. 2012. ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53. Nature Chemical Biology 8:646–654. doi: 10.1038/nchembio.965
67. Sun L, Tian Z, Wang J. 2010. A direct cross-talk between interferon-g and sonic hedgehog signaling that leads to the proliferation of neuronal precursor cells. Brain, Behavior, and Immunity 24:220–228. doi: 10.1016/j.bbi.2009.09.016
68. Tan YH, Schneider EL, Tischfield J, Epstein CJ, Ruddle FH. 1974a. Human chromosome 21 dosage: effect on the expression of the interferon induced antiviral state. Science 186:61–63. doi: 10.1126/science.186.4158.61
69. Tan YH, Tischfield JA, Ruddle FH. 1974b. Proceedings: The genetics of the antiviral state in human cells. Cytogenetics and Cell Genetics 13:158–159. doi: 10.1159/000130262
70. Tanaka MH, Giro EM, Cavalcante LB, Pires JR, Apponi LH, Valentini SR, Spolidório DM, Capela MV, Rossa C, Scarel-Caminaga RM. 2012. Expression of interferon-g, interferon-a and related genes in individuals with Down syndrome and periodontitis. Cytokine 60:875–881. doi: 10.1016/j.cyto.2012.08.020
71. Taylor MW, Tsukahara T, Brodsky L, Schaley J, Sanda C, Stephens MJ, McClintick JN, Edenberg HJ, Li L, Tavis JE, Howell C, Belle SH. 2007. Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy. Journal of Virology 81: 3391–3401. doi: 10.1128/JVI.02640-06
72. Tefferi A, Litzow MR, Pardanani A. 2011. Long-term outcome of treatment with ruxolitinib in myelofibrosis. The New England Journal of Medicine 365:1455–1457. doi: 10.1056/NEJMc1109555
73. Tisserand J, Khetchoumian K, Thibault C, Dembélé D, Chambon P, Losson R. 2011. Tripartite motif 24 (Trim24/ Tif1a) tumor suppressor protein is a novel negative regulator of interferon (IFN)/signal transducers and activators of transcription (STAT) signaling pathway acting through retinoic acid receptor a (Rara) inhibition. Journal of Biological Chemistry 286:33369–33379. doi: 10.1074/jbc.M111.225680
74. Troca-Marí n JA, Casañas JJ, Benito I, Montesinos ML. 2014. The Akt-mTOR pathway in Down’s syndrome: the potential use of rapamycin/rapalogs for treating cognitive deficits. CNS & Neurological Disorders - Drug Targets 13:34–40. doi: 10.2174/18715273113126660184
75. Uphoff CC, Drexler HG. 2002. Detection of mycoplasma in leukemia-lymphoma cell lines using polymerase chain reaction. Leukemia 16:289–293. doi: 10.1038/sj.leu.2402365
76. van Riggelen J, Yetil A, Felsher DW. 2010. MYC as a regulator of ribosome biogenesis and protein synthesis. Nature Reviews Cancer 10:301–309. doi: 10.1038/nrc2819
77. Volk M, Maver A, Lovrečić L, Juvan P, Peterlin B. 2013. Expression signature as a biomarker for prenatal diagnosis of trisomy 21. PLoS One 8:e74184. doi: 10.1371/journal.pone.0074184
78. Waddell SJ, Popper SJ, Rubins KH, Griffiths MJ, Brown PO, Levin M, Relman DA. 2010. Dissecting interferon-induced transcriptional programs in human peripheral blood cells. PLoS One 5:e9753. doi: 10.1371/journal.pone.0009753
79. Walsh D, Mathews MB, Mohr I. 2013. Tinkering with translation: protein synthesis in virus-infected cells. Cold Spring Harbor Perspectives in Biology 5:a012351. doi: 10.1101/cshperspect.a012351
80. Wang J, Duncan D, Shi Z, Zhang B. 2013. WEB-based GEne SeT anaLysis toolkit (WebGestalt): update 2013. Nucleic Acids Research 41:W77–83. doi: 10.1093/nar/gkt439
81. Wang L, Wang S, Li W. 2012. RSeQC: quality control of RNA-seq experiments. Bioinformatics 28:2184–2185. doi: 10.1093/bioinformatics/bts356
82. Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpé S, Maes M. 2005. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Molecular Psychiatry 10:538–544. doi: 10.1038/sj.mp.4001600
83. Wichers MC, Maes M. 2004. The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression. Journal of Psychiatry & Neuroscience 29:11–17.
84. Wiseman FK, Al-Janabi T, Hardy J, Karmiloff-Smith A, Nizetic D, Tybulewicz VL, Fisher EM, Strydom A. 2015. A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. Nature Reviews Neuroscience 16:564–574. doi: 10.1038/nrn3983
85. Wörle H, Maass E, Köhler B, Treuner J. 1999. Interferon alpha-2a therapy in haemangiomas of infancy: spastic diplegia as a severe complication. European Journal of Pediatrics 158:344. doi: 10.1007/s004310051089
86. Yao Y, Higgs BW, Richman L, White B, Jallal B. 2010. Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNa antibody, in systemic lupus erythematosus. Arthritis Research & Therapy 12 Suppl 1:S6. doi: 10.1186/ar2887
87. Zhang B, Kirov S, Snoddy J. 2005. WebGestalt: an integrated system for exploring gene sets in various biological contexts. Nucleic Acids Research 33:W741–748. doi: 10.1093/nar/gki475
88. Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. 2015. Type I interferons in anticancer immunity. Nature Reviews Immunology 15:405–414. doi: 10.1038/nri3845